Follow
Colin Erdman
Colin Erdman
Technical Lead, AdverseEvents, Inc.
Verified email at adverseevents.com
Title
Cited by
Cited by
Year
The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010
KB Hoffman, M Dimbil, CB Erdman, NP Tatonetti, BM Overstreet
Drug safety 37, 283-294, 2014
1482014
The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010
KB Hoffman, M Dimbil, CB Erdman, NP Tatonetti, BM Overstreet
Drug safety 37, 283-294, 2014
1482014
Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS)
KB Hoffman, AR Demakas, M Dimbil, NP Tatonetti, CB Erdman
Drug safety 37, 971-980, 2014
732014
Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012
KB Hoffman, A Demakas, CB Erdman, M Dimbil, PM Doraiswamy
Bmj 347, 2013
382013
A drug safety rating system based on postmarketing costs associated with adverse events and patient outcomes
KB Hoffman, M Dimbil, RF Kyle, NP Tatonetti, CB Erdman, A Demakas, ...
Journal of Managed Care & Specialty Pharmacy 21 (12), 1134-1143c, 2015
102015
System and method for surveillance and evaluation of safety risks associated with medical interventions
KB Hoffman, BM Overstreet, CB Erdman, R Kyle
US Patent App. 14/279,105, 2014
72014
Post-approval adverse events of new and old anticoagulants
KB Hoffman, A Demakas, CB Erdman, M Dimbil
BMJ 348, 2014
32014
System and Method for Surveillance and Evaluation of Safety Risks Associated with Medical Interventions
KB Hoffman, BM Overstreet, CB Erdman, R Kyle
US Patent App. 14/752,452, 2015
22015
Neuropsychiatric adverse effects in FDA reporting system
A VULGARIS
BMJ 347, 21, 2013
2013
Tamiflu correspondence with Roche
KB Hoffman, A Demakas, CB Erdman, M Dimbil, P Murali
2013
The system can't perform the operation now. Try again later.
Articles 1–10